Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 2/2021

01-04-2021 | Interferon | Interpretive Synthesis Review Article

MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity

Author: Kamal U. Saikh

Published in: Immunologic Research | Issue 2/2021

Login to get access

Abstract

The continuous emergence of infectious pathogens along with antimicrobial resistance creates a need for an alternative approach to treat infectious diseases. Targeting host factor(s) which are critically involved in immune signaling pathways for modulation of host immunity offers to treat a broad range of infectious diseases. Upon pathogen-associated ligands binding to the Toll-like/ IL-1R family, and other cellular receptors, followed by recruitment of intracellular signaling adaptor proteins, primarily MyD88, trigger the innate immune responses. But activation of host innate immunity strongly depends on the correct function of MyD88 which is tightly regulated. Dysregulation of MyD88 may cause an imbalance that culminates to a wide range of inflammation-associated syndromes and diseases. Furthermore, recent reports also describe that MyD88 upregulation with many viral infections is linked to decreased antiviral type I IFN response, and MyD88-deficient mice showed an increase in survivability. These reports suggest that MyD88 is also negatively involved via MyD88-independent pathways of immune signaling for antiviral type I IFN response. Because of its expanding role in controlling host immune signaling pathways, MyD88 has been recognized as a potential drug target in a broader drug discovery paradigm. Targeting BB-loop of MyD88, small molecule inhibitors were designed by structure-based approach which by blocking TIR–TIR domain homo-dimerization have shown promising therapeutic efficacy in attenuating MyD88-mediated inflammatory impact, and increased antiviral type I IFN response in experimental mouse model of diseases. In this review, we highlight the reports on MyD88-linked immune response and MyD88-targeted therapeutic approach with underlying mechanisms for controlling inflammation and antiviral type I IFN response.

Highlights

• Host innate immunity is activated upon PAMPs binding to PRRs followed by immune signaling through TIR domain–containing adaptor proteins mainly MyD88.
• Structure-based approach led to develop small-molecule inhibitors which block TIR domain homodimerization of MyD88 and showed therapeutic efficacy in limiting severe inflammation-associated impact in mice.
• Therapeutic intervention of MyD88 also showed an increase in antiviral effect with strong type I IFN signaling linked to increased phosphorylation of IRFs via MyD88–independent pathway.
• MyD88 inhibitors might be potentially useful as a small-molecule therapeutics for modulation of host immunity against inflammatory diseases and antiviral therapy.
• However, prior clinical use of more in-depth efforts should be focused for suitability of the approach in deploying to complex diseases including COPD and COVID-19 in limiting inflammation-associated syndrome to infection.
Literature
1.
Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–15.PubMed
2.
3.
Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol. 2012;30:491–529.PubMedPubMedCentral
4.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.PubMed
5.
Honda K, Taniguchi T. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6(9):644–58.PubMed
6.
Takeda K, Kaisho T. Akira S Toll-like receptors. Annu Rev Immunol. 2003;21:335–76.PubMed
7.
Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene. 1990;5:1095–7.PubMed
8.
Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 1997;278:1612–5.PubMed
9.
Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997;7:837–47.PubMed
10.
Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6(9):644–58.PubMed
11.
Watters TM, Kenny EF, O’Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol. 2007;85(6):411–9.PubMed
12.
Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res. 2011;90(4):417–27.PubMedPubMedCentral
13.
Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 2001;413(6851):78–83.PubMed
14.
Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002;420(6913):329–33.PubMed
15.
Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301(5633):640–3.PubMed
16.
Yamamoto M. Sato, S, Hemmi H, , et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol. 2003;4(11):1144–50.PubMed
17.
O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7(5):353–64.PubMed
18.
Janassens S, Beyart R. A universal role of Myd88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci. 2002;27:474–82.
19.
Brown J, Wang H, Hajishshengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases and cross-talk. J Dent Res. 2011;90:417–27.PubMedPubMedCentral
20.
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.PubMed
21.
Dunne A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003;171:re3.
22.
Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253–8.PubMed
23.
Hardiman G, Rock FL, Balasubramanian S, Kastelein RA, Bazan F. Molecular characterization and modular analysis of human MyD88. Oncogene. 1996;13:2467–75.PubMed
24.
Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med. 2003;197:263–8.PubMedPubMedCentral
25.
Avbelj M, Horvat S, Roman Jerala R. The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs. J Immunol. 2011;187:2394–404.PubMed
26.
Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253–8.PubMed
27.
Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, Tschopp J. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998;273:12203–9.PubMed
28.
Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4- IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:885–90.PubMedPubMedCentral
29.
Xu Y, Tao X, Shen B, Horng, T, Medzhitov R, Manley JL, and Tong, L. Structural Basis for Signal Transduction by the Toll-interleukin-I receptor domains. Nature. 2000;408:111–115.
30.
Adachi O, Kawai T, Takeda KK, Matsumuto M, Tsutsui H, Sakagami M, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9:143–50.PubMed
31.
Sun D, Ding A. MyD88-mediated stabilization of interferon-γ-induced cytokine and chemokine mRNA. Nat Immunol. 2006;7:375–81.PubMed
32.
Liu X, Zhan Z, Li D, Xu L, Ma F, et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12:416–24.PubMed
33.
Hassan GS, Mourad W. An unexpected role for MHC class II. Nat Immunol. 2011;12:375–6.PubMed
34.
Mourad W, Geha RS. Chatila T Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med. 1990;172:1513–6.PubMed
35.
Spertini F, Chatila T, Geha RS. Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells. 1992. J Immunol. 1992;149:65–70.PubMed
36.
Hauschildt S, Bessler WG. Scheipers P (1993) Engagement of major histocompatibility complex class II molecules leads to nitrite production in bone marrow-derived macrophages. Eur J Immunol. 1993;23:2988–92.PubMed
37.
Ulrich RG, Bavari S. Olson MA (1995) Bacterial superantigens in human disease: structure, function and diversity. Trends Microbiol. 1995;3:463–8.PubMed
38.
Stiles BG, Bavari S, Krakauer T, Ulrich RG. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect Immun. 1993;61:5333–8.PubMedPubMedCentral
39.
Kissner TL, Ruthel G, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. MyD88-dependent pro-inflammatory cytokine response contributes to lethal toxicity of staphylococcal enterotoxin B in mice. Innate Immun. 2011;17:451–62.PubMed
40.
Kissner TL, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. Staphylococcal enterotoxin A induction of pro-inflammatory cytokines and lethality in mice is primarily dependent on MyD88. Immunol. 2010;130:516–26.
41.
Kissner TL, Ruthel G, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. Activation of MyD88 signaling upon Staphylococcal enterotoxin binding to MHC class II molecules. PLoS ONE. 2011;6(1):e15985.PubMedPubMedCentral
42.
Kissner TL, Moisan L, Mann E, Ulrich RG, Ping S, Waugh DS, Rebek M, Rebek J, Saikh KU. A small molecule that mimics the BB-loop in Toll/IL-1 receptor domain of MyD88 attenuate Staphylococcal enterotoxin induced cytokine production and toxic shock in mice. J BiolChem. 2011;286:31385–96.
43.
Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000;408:111–5.PubMed
44.
Bartfai T, Behrens MM, Gaidarova S, Pemberton J, Shivanyuk A, Rebek J Jr. A low molecular weight mimic of the TIR-domain inhibits interleukin 1 receptor-mediated responses. Proc Natl Acad Sci USA. 2003;100:7971–6.PubMedPubMedCentral
45.
Kissner TL, Ruthel G, Alam S, Mann E, Ajami DE, Rebek M, Larkin ES, Fernandez S, Ulrich RG, Ping S, Waugh DS, J Rebek Jr, Saikh KU. Therapeutic inhibition of pro-inflammatory signaling and toxicity to staphylococcal enterotoxin B by a synthetic dimeric BB-loop mimetic of MyD88. PLoS ONE. 2012;7(7):e40773.PubMedPubMedCentral
46.
Davis CN, Mann E, Behrens MM, Gaidarova S, Rebek M, Rebek J Jr, Bartfai T. MyD88- dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc Natl Acad Sci U S A. 2006;103:2953–8.PubMedPubMedCentral
47.
Alam S, Javor S, Degardin M, Ajami D, Rebek M, Kissner TL, Waag DM, Rebek J Jr, Saikh KU. Structure-based design and synthesis of a small molecule that exhibits anti-inflammatory activity by inhibition of MyD88- mediated signaling to bacterial toxin exposure. Chem Biol Drug Design. 2015;86:200–9.
48.
Saikh, KU., Rebek, JM, Glass PJ. Small molecule inhibitor of MyD88 for therapeutic treatment against alphavirus and staphylococcal enterotoxin infections and toxin exposure. Patent# US 9,833,437 B2.
49.
Ryan DA, Degardin M, Alam S, Kissner TL, Hale M, Cameron MD, Rebek M, Ajami D, Saikh KU, Rebek J Jr. Rational design of peptide derivatives for inhibition of MyD88-mediated TLR signaling in human PBMCs and epithelial cells exposed to F. tularensis. ChemBiol Drug Des. 2017;90(6):1190–205.
50.
51.
Padova FD, Quesniaux VFJ, Ryffel B. MyD88 as a therapeutic target for inflammatory diseases. Expert OpinTher Targets. 2018;25:401–8.
52.
Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007;82:801–10.PubMed
53.
Loiarro M, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependentactivation of NF-{kappa}. B J BiolChem. 2005;280:15809–14.
54.
Van Tassell BW, Seropian IM, Toldo S, Salloum FN, Smithson L, Varma A, Hoke NN, Gelwix C, Chau V, Abbate AJ. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. Cardiovasc Pharmacol. 2010 Apr;55(4):385–90. https://​doi.​org/​10.​1097/​FJC.​0b013e3181d3da24​ (PMID: 20125030).CrossRef
55.
Lin Xie , Feng-Chao Jiang , Li-Min Zhang , Wen-Tao He , Jian-Hua Liu , Ming-Qiang Li , Xue Zhang , Shuai Xing, Hui Guo , Ping Zhou. .Targeting of My88 homodimerization by novel synthetic inhibitor TJ-M2010–5 in preventing colitis-associated colorectal cancer. J Natl Cancer Inst. 2015 Dec 28;108 (4):djv364. doi: https://​doi.​org/​10.​1093/​jnci/​djv364. Print 2016 Apr.
56.
Greg A. Snyder, Lindsey J. Brown, Savannah Taylor, Ciara E. Faupel, Matthew Sherman, Justin J. Montague, Kamal Saikh and Yajing Wang. Targeting of diffuse large B-cell lymphomas using MyD88 small molecule inhibitors. J. Immunol. May 1, 2018, 2019 (1 Supplement) 169.17
57.
TenOver BR. The Evolution of antiviral defense systems. Cell Host Microbe. 2016;19:142–9.
58.
Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev immunol. 2002;20:197–216.PubMed
59.
60.
Takeda A, Yanai H. Interferon signaling network in innate defense. Cell Microbiol. 2006;8:907–22.
61.
Brierle MM, Fish EN. IFN- alpha beta receptor interactions to biologic outcomes; understanding the circuitry. J Interferon Cytokine Res. 2002;22:835–45.
62.
Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50:907–23.PubMedPubMedCentral
63.
64.
65.
66.
Sallard E, Lescure F-X, Yazdanapanah Y, Mentre F, Peiffer-Smadja N. Antiviral Res. 2020;178:10479.
67.
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;2001(19):623–55.
68.
Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome mediated degradation. Mol Cell Biol. 1998;18:2986–96.PubMedPubMedCentral
69.
Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 1997;1997(8):293–312.
70.
Mamane Y, Heylbroeck C, Génin P, Algarté M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R, Hiscott J. Interferon regulatory factors: the next generation. Gene. 1999;237:1–14.PubMed
71.
Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-1 interferon-dependent immune responses. Nature. 2005;434:772–7.PubMed
72.
Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKK epsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4:491–6.PubMed
73.
Siednienko J, Halle A, Nagpal K, Golenbock DT, Miggin SM. TLR3-mediated IFN-β gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like. Eur J Immunol. 2010;2010(40):3150–60.
74.
Siednienko J, Gajanayake T, Fitzgerald KA, Moynagh P, Miggin SM. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-β and RANTES production. J Immunol. 2011;186:2514–22.PubMed
75.
Planès R, Ben Haij N, Leghmari K, Serrero M, BenMohamed L, Bahraoui E. HIV-1 Tat protein activates both the MyD88 and TRIF pathways to induce tumor necrosis factor alpha and interleukin-10 in human monocytes. J Virol. 2016;2016(90):5886–98.
76.
Singh MV, Cicha MZ, Meyerholz DK, Chapleau MW, Abboud FM. Dual activation of TRIF and MyD88 adaptor proteins by angiotensin II evokes opposing effects on pressure, cardiac hypertrophy, and inflammatory gene expression. Hypertension. 2015;66:647–56.PubMed
77.
Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O’Neill LA. MyD88 adaptor like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol. 2009;183:3642–51.PubMed
78.
Johnson AC, Li X, Pearlman E. MyD88 functions as a negative regulator of TLR3/TRIFinduced corneal inflammation by inhibiting activation of c-Jun N-terminal kinase. J Biol Chem. 2003;278:3988–39960.
79.
Saito T, Gale M Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp Med. 2008;205:1523–7.
80.
Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, Chen M, Yeh WC, Akira S, Liu PP. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3 induced myocarditis and influences type I interferon production. Circulation. 2005;112:2276–85.PubMed
81.
Sharma A, Maheshwari R. Oligonucleotide array analysis of Toll-like receptors and associated signaling genes in Venezuelan equine encephalitis virus-infected mouse brain. J Gen Virol. 2009;2009(90):1836–47.
82.
Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF. Differential regulation of interferon responses by ebola and Marburg virus VP35 proteins. Cell Rep. 2016;14:1632–40.PubMedPubMedCentral
83.
84.
Ayithan N, Bradfute SB, Anthony SM, Stuthman KS, Dye JM, Bavari S, Bray M, Ozato K. Ebola virus-like particles stimulate type I interferons and pro-inflammatory cytokine expression through the toll-like receptors and interferon signaling pathways. J Interferon Cytokine Res. 2014;34:79–89.PubMedPubMedCentral
85.
Ribero MS, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and type I interferon response. Plos Pathogens. 2020;16:e1008737.
86.
Whitmore A, Agnihothram S, et al., (2015) Toll-like receptor signaling via TRIF contributes to a protective innate immune response to sever acute respiratory syndrome coronavirus infection. mBio. 6: e00638-15.
87.
Acharya D, Liu GO, Gack MU. Dysregulation of type I interferon responses in Covid-19. Nat Immunol. 2020;20:397–8.
88.
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Jean K, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:136–45.
89.
Iampietro M, Aurine N, Dhondt KP, Dumont C, Pelissier R, Spanier J, Valive A, Raoul H, kalinke U, Horvat B. Control of nipah virus infection in mice by the host adaptors mitrochondrial antiviral signaling protein (MAVS) and myeloid differentiation primary response 88 (MyD88). J. Infect. Dis. 2019.Suppl. S1–6.
90.
Zhou ZX, Zhang BC, Sun L. Poly (I:C) induces antiviral immune responses in Japanese flounder (Paralichthysolivaceus) that require TLR3 and MDA5 and is negatively regulated by MyD88. PLoS One. 2014;9:e112918.PubMedPubMedCentral
91.
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses Nat. Rev Immunol. 2014;14(36):49.
92.
93.
Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–5.PubMedPubMedCentral
94.
95.
Martinez-Gil L, Ayllon J, Ortigoza MB, Garcia-satre A, Shaw ML, Palese P. Identification of small molecules with type I interferon inducing properties by High-throughput Screening. Plos one. 2012;7(11):e49049.PubMedPubMedCentral
96.
97.
98.
Kaufmann SHE, Dorhai A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev. 2018;17:35–55.
99.
Sousa CP, Brites C. Immune response in SARS-CoV-2 infection: the role of interferons type I and type III. Braz J Infect Dis. 2020;24(5):428–33.
100.
Hadjadji J, Yatim N, Barnabel L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.
101.
Dasgupta, A. Seeking an Early COVID-19 drug, researchers look to interferons. The Scientist Magazine, 2020
Metadata
Title
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
Author
Kamal U. Saikh
Publication date
01-04-2021
Publisher
Springer US
Keyword
Interferon
Published in
Immunologic Research / Issue 2/2021
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-021-09188-2

Other articles of this Issue 2/2021

Immunologic Research 2/2021 Go to the issue

Original Article

Dexmedetomidine alleviates pulmonary edema through the epithelial sodium channel (ENaC) via the PI3K/Akt/Nedd4-2 pathway in LPS-induced acute lung injury

Original Article

Association of interleukin-12B rs6887695 with susceptibility to allergic rhinitis

Original Article

Exploring genetic defects in adults who were clinically diagnosed as severe combined immune deficiency during infancy

Original Article

Dysregulation of circulating follicular helper T cells in type 2 diabetic patients with diabetic retinopathy

Original Article

Late-onset autoimmune polyendocrine syndrome type 1: a case report and literature review

Review

Iodoprophylaxis and thyroid autoimmunity: an update